Houston, TX- January 1, 2015. SpectraCell Laboratories recently launched a major expansion of its specialized testing test menu to include several new diagnostic panels. These include cardiometabolic biomarkers, pre-diabetic screening, male and female hormone panels, thyroid, and adrenal function and cardiovascular-related genetic tests. The new tests complement SpectraCell’s flagship micronutrient testing which measures nutritional status at the cellular level.“ Our main goal is to provide a complete personalized picture – the SpectraCell Solution.
We give our clients as many pieces of the diagnostic puzzle as possible so that a broader assessment of the patient’s health emerges.” states William Stanberry, CEO. “Adding these new tests will contribute to improved patient outcomes.”
The cardiometabolic and pre-diabetes panels include well established biomarkers that measure a person’s likelihood of developing diabetes or heart disease, or the degree to which these conditions may already exist. Three main areas of metabolic function are tested: (1) glycemic control (blood sugar regulation), (2) lipoprotein metabolism and (3)vascular inflammation (damage to blood vessels). Each person is also given a risk score depending on their results. This scoring aspect of the cardiometabolic panel is a unique feature by SpectraCell that enables a doctor and patient to monitor their progress at a glance. SpectraCell’s hormone panels measure well-known steroid hormones such as testosterone and estrogen, and several lesser known but equally important regulating and precursor hormones. The thyroid panel tests for common thyroid hormones and also thyroid antibodies which help identify autoimmune disease. SpectraCell’s comprehensive hormone testing pinpoints the precise place of imbalance in the complicated hormonal cascade. Nutritional deficiencies will negatively impact hormone production and efficiency, so combining hormone tests with micronutrient testing is particularly important.
In addition, SpectraCell testing can now detect the presence of two genes – Factor VLeiden and Prothrombin – that indicate a risk of developing blood clots, deep veinthrombosis or heart attacks. These markers are particularly relevant for certain demographics such as pregnant women or those with a history of clotting issues. SpectraCell already tests for two other genes – MTHFR and ApoE – that are linked with cardiovascular and neurological conditions. The company also offers telomere testing, which assesses cellular aging. As the understanding of the importance of advanced diagnostic testing increases,SpectraCell continues to grow, now serving over 5,000 physicians nationwide. More information on ordering any of the new tests can be found at www.spectracell.com.
About SpectraCell Laboratories – SpectraCell is a CLIA accredited laboratory thatoffers advanced clinical testing to healthcare providers and consumers nationwide.SpectraCell’s diagnostic testing is relevant in prevention, as well as the treatment and management of disease since it offers cellular nutritional analysis via its flagship Micronutrient Test, cardiovascular diagnostics, hormone panels and genetic testing. Dedicated to research and development, SpectraCell also provides innovative diagnosticanalyses in the emerging field of anti-aging medicine.